SXC-2023

DRUG5 trials

Sponsors

Promentis Pharmaceuticals, Inc., National Institute on Drug Abuse (NIDA)

Conditions

Cocaine Use DisorderHealthyHealthy VolunteersImpulse Control DisordersTrichotillomania

Phase 1

Placebo-Controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of SXC-2023 in Healthy Volunteers

CompletedNCT03301298

Promentis Pharmaceuticals, Inc.Healthy

Start: 2017-09-11End: 2018-02-13Updated: 2019-09-26

Randomized, Double-Blind, Placebo-Controlled, MAD Study to Assess the Safety, Tolerability, and Pharmacokinetics of SXC 2023

CompletedNCT03542435

Promentis Pharmaceuticals, Inc.Healthy Volunteers

Start: 2018-04-26End: 2018-09-10Updated: 2018-10-16

SXC-2023 Cocaine Interaction Study

CompletedNCT06343532

National Institute on Drug Abuse (NIDA)Cocaine Use Disorder

Start: 2024-10-08End: 2024-12-30Updated: 2026-04-24

Phase 2

A Study in Patients With Trichotillomania

CompletedNCT03797521

Promentis Pharmaceuticals, Inc.Trichotillomania

Start: 2018-12-19End: 2019-12-16Updated: 2021-10-28

Restoring Cognitive Control (ReCon) in Acute Nicotine Withdrawal

CompletedNCT03887429

Promentis Pharmaceuticals, Inc.Impulse Control Disorders

Start: 2019-03-04End: 2019-07-09Updated: 2020-07-17